BioAge's BGE-102 was shown to complement existing therapies, specifically GLP-1 agonists.
3 reports, 3 independent
Updated Jun 30
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioAge's BGE-102 was shown to complement existing therapies, specifically GLP-1 agonists.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.BioAge Labs started Phase 2 study QUELL-CV for BGE-102.1 source
BioAge's BGE-102 demonstrated potential to complement GLP-1 agonist treatments.1 source
Preclinical data shows BioAge's BGE-102 complements GLP-1 agonists for weight loss.1 source
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- yahoo.com
- Clinical Trials ArenaBioAge commences dosing in trial of obesity treatment candidate BGE-102 BioAge Labs has dosed the first subject in the randomised Phase I study of BGE-102, an orally available small molecule designed
- GlobeNewswireBioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor First-in-human study evaluating safety, tolerability, pharmacokinetics, and